Synergy Pharmaceuticals (NASDAQ:SGYP) is set to post its quarterly earnings results after the market closes on Thursday, November 8th. Analysts expect Synergy Pharmaceuticals to post earnings of ($0.13) per share for the quarter.
Synergy Pharmaceuticals (NASDAQ:SGYP) last issued its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.03. The firm had revenue of $12.25 million for the quarter, compared to analyst estimates of $10.20 million. On average, analysts expect Synergy Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of NASDAQ SGYP opened at $0.44 on Wednesday. The company has a market cap of $111.60 million, a P/E ratio of -0.44 and a beta of 2.38. Synergy Pharmaceuticals has a 52-week low of $0.36 and a 52-week high of $3.10.
Several research analysts have recently weighed in on SGYP shares. Zacks Investment Research upgraded shares of Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 10th. BidaskClub cut shares of Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Synergy Pharmaceuticals in a report on Tuesday, August 7th. BTIG Research cut shares of Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Friday, October 26th. Finally, Canaccord Genuity cut shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 26th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company. Synergy Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $8.17.
WARNING: “Synergy Pharmaceuticals (SGYP) Scheduled to Post Quarterly Earnings on Thursday” was originally published by Enterprise Leader and is the sole property of of Enterprise Leader. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://theenterpriseleader.com/2018/11/07/synergy-pharmaceuticals-sgyp-scheduled-to-post-quarterly-earnings-on-thursday.html.
About Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.
Featured Story: Trading Strategy Examples and Plans
Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.